Yanan Zhu
Stock Analyst at Wells Fargo
(0.85)
# 3,595
Out of 4,814 analysts
72
Total ratings
24.07%
Success rate
-18.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Initiates: Overweight | $115 | $53.79 | +113.79% | 1 | Apr 11, 2025 | |
| RGLS Regulus Therapeutics | Upgrades: Overweight | $3 → $6 | $2.04 | +194.12% | 1 | Mar 27, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $2 → $1.5 | $0.24 | +518.05% | 2 | Mar 21, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $1.43 | +319.58% | 3 | Mar 21, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $25 → $20 | $1.52 | +1,220.13% | 2 | Mar 18, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $3.16 | +216.96% | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $58 → $50 | $10.51 | +375.74% | 6 | Mar 7, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.12 | +257.14% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $13.00 | +130.77% | 2 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $60 → $50 | $7.27 | +588.23% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $5 | $4.15 | +20.48% | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $15 | $0.73 | +1,954.79% | 6 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $1.29 | +211.28% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $4 | $0.79 | +406.46% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $28.32 | +171.89% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $12.65 | +216.21% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $37.76 | +72.14% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.00 | +650.00% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $3.07 | +714.33% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $26.67 | +87.48% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.71 | +466.41% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.51 | +17,828.29% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $105 | $16.25 | +546.15% | 2 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $1.25 | +700.00% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $593.60 | -45.08% | 1 | Feb 2, 2021 |
Sarepta Therapeutics
Apr 11, 2025
Initiates: Overweight
Price Target: $115
Current: $53.79
Upside: +113.79%
Regulus Therapeutics
Mar 27, 2025
Upgrades: Overweight
Price Target: $3 → $6
Current: $2.04
Upside: +194.12%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.24
Upside: +518.05%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $1.43
Upside: +319.58%
Metagenomi
Mar 18, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $1.52
Upside: +1,220.13%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.16
Upside: +216.96%
Arcturus Therapeutics Holdings
Mar 7, 2025
Maintains: Overweight
Price Target: $58 → $50
Current: $10.51
Upside: +375.74%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.12
Upside: +257.14%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $13.00
Upside: +130.77%
Intellia Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $7.27
Upside: +588.23%
Feb 24, 2025
Maintains: Equal-Weight
Price Target: $40 → $5
Current: $4.15
Upside: +20.48%
Dec 12, 2024
Maintains: Overweight
Price Target: $20 → $15
Current: $0.73
Upside: +1,954.79%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.29
Upside: +211.28%
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $0.79
Upside: +406.46%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $28.32
Upside: +171.89%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $12.65
Upside: +216.21%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $37.76
Upside: +72.14%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $4.00
Upside: +650.00%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $3.07
Upside: +714.33%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $26.67
Upside: +87.48%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.71
Upside: +466.41%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.51
Upside: +17,828.29%
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $16.25
Upside: +546.15%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $1.25
Upside: +700.00%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $593.60
Upside: -45.08%